Clinical trial
A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP)…
NCT00140894 · Merck Sharp & Dohme LLC, Industry · Terminated
Key facts
| NCT number | NCT00140894 |
|---|---|
| Title | A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED) |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Rofecoxib in Familial Adenomatous Polyposis (FAP) |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Adenomatous Polyposis Coli |
| Intervention type | Drug |
| Interventions | MK0966, rofecoxib / Duration of Treatment: 24 weeks, Comparator: placebo / Duration of Treatment: 24 weeks |
| Enrollment | 62 |
| Start date | Aug 6, 2002 |
| Completion | Oct 11, 2004 |
| First posted | Sep 1, 2005 |
| Last update posted | Sep 20, 2019 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: